Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

• Status: Recruiting
• Trial end date: 2022-12-01

Summary

The purpose of the study is to evaluate the efficacy and toxicity of fludarabine with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum resistant or refractory ovarian cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Doxorubicin; Fludarabine; Fludarabine phosphate; Liposomal doxorubicin; Vidarabine